Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad®)

Human Vaccines

Volumn 2, Issue 5, 2006, Pages 205-214

  Kuter, Barbara J ^a   Brown, Michelle L Hoffman ^a   Hartzel, Jonathan ^a   Williams, Wendy R ^a   Eves, Karen A ^a   Black, Steve ^b   Shinefield, Henry ^b,f   Reisinger, Keith S ^c,f   Marchant, Colin D ^d   Sullivan, Bradley J ^e   Thear, Marci ^a   Klopfer, Stephanie ^a   Xu, Jin ^a   Gress, Jacqueline O ^a   Schödel, Florian ^a   Allen, Brian K ^f   Alvey, Justin C ^f   Anderson, Edwin L ^f   Andrews, Wilson P ^f   Asmar, Basim ^f   Azimi, Parvin H ^f   Ball, Charles S ^f   Barone, Stephen R ^f   Bernstein, Henry ^f   Bernstein, Jerry C ^f   Bettis, Robert ^f   Black, Steven ^f   Blatter, Mark M ^f   Block, Stan ^f   Blumer, Jeffrey L ^f   Boehm, Frederick P ^f   Brayden, Robert ^f   Bromberg, Kenneth ^f   Buttler, John L ^f   Chatterjee, Archana ^f   Conti, Ralph ^f   Coury, Daniel L ^f   Danhauer, David E ^f   Daum, Robert S ^f   Dennehy, Penelope ^f   Dionne, Marc ^f   Eckert, Buckley ^f   Edwards, Kathryn M ^f   Ford, Robert V ^f   Fries, Stephen M ^f   Goessler, Mary C ^f   Greenberg, David P ^f   Guerra, Fernando A ^f   Guerrero, Juan ^f   Halperin, Scott ^f   Henderson, Frederick W ^f   Hornick, Richard ^f   Iwaishi, Louise K ^f   Johnson, Candice E ^f   Jones, Ronald C ^f   Karasov, Robert ^f   Law, Barbara ^f   Leader, Joseph ^f   Lebel, Mark ^f   Leiberman, Jay ^f   Lepow, Martha ^f   Luber, Stephen ^f   Marchant, Colin ^f   Marshall, Gary S ^f   Matson, David O ^f   Meissner, H Cody ^f   Milnes, Philip D ^f   Moore, William ^f   Nachman, Sharon A ^f   Nauert, Beth ^f   Perrin, Keith ^f   Pollara, Bernard ^f   Rathore, Mobeen H ^f   Rees, William C ^f   Rennels, Margaret ^f   Rothstein, Edward ^f   Rudoy, Raul ^f   Russell, Margaret ^f   Ryan, Michael E ^f   Sawyer, Mark ^f   Senders, Shelly D ^f   Shapiro, Steven A ^f   Sher, Lawrence ^f   Silas, Peter E ^f   Sperling, Malcolm J ^f   Stewart, Tracy ^f   Sullivan, Bradley ^f   Taylor, James A ^f   Thompson, Steven M ^f   Troutman, James L ^f   Vaughn, Katherine F ^f   Venters, Charmaine L ^f   Walter, Emmanuel ^f   Watson, Barbara ^f   Werzberger, Alan ^f   Wheeler, J Gary ^f   Williams, Karen R ^f   Yeiser, Michael F ^f   Yogev, Ram ^f   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b KAISER PERMANENTE   (United States)

^c Primary Physicians Research   (United States)

^d BOSTON MEDICAL CENTER   (United States)

^e MARSHFIELD CLINIC   (United States)

^f NONE

Author keywords

Combination vaccines; Measles; Mumps; Rubella; Varicella

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; M M R II; MEASLES MUMPS RUBELLA VACCINE; MEASLES MUMPS RUBELLA VARICELLA VACCINE; PROQUAD; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIBODY RESPONSE; ARTICLE; BRONCHIOLITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEBRILE CONVULSION; FEVER; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; INCIDENCE; INFANT; INJECTION PAIN; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE SWELLING; MEASLES LIKE RASH; MULTICENTER STUDY; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RASH; RUBELLA LIKE RASH; SINGLE DRUG DOSE; VARICELLA LIKE RASH;

EID: 33751202162     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.2.5.3246     Document Type: Article

References (55)

1. Centers for Disease Control and Prevention. Combination vaccines for childhood immunization: Recommendations of the advisory committee on immunization practices (ACIP), the American academy of pediatrics (AAP), and the American academy of family physicians (AAFP). Morbidity and Mortality Weekly Report 1999; 48:1-16.
2. Decker MD. Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr Inf Dis J 2001; 20:S10-8.
3. Pellissier JM, Coplan PM, Jackson LA, May JE. The effect of additional shots on the vaccine administration process: Results of a time-motion study in 2 settings. Am J Manag Care 2000; 6:1038-44.
4. Meyerhoff AS, Weniger BG, Jacobs RJ. Economic value to parents of reducing the pain and emotional distress of childhood vaccine injections. Pediatr Inf Dis J 2001; 20:S57-62.
5. Dietz VJ, Stevenson J, Zell ER, Cochi S, Hadler S, Eddins D. Potential impact on vaccination coverage levels by administering vaccines simultaneously and reducing dropout rates. Arch Pediatr Adolesc Med 1994; 148:943-9.
6. Davis RL, Coplan P, Mell L, Black S, Shinefield H, Lewis E. Impact of the introduction of a combined haemophilus B conjugate vaccine and hepatitis B recombinant vaccine on vaccine coverage rates in a large west coast health maintenance organization. Ped Infect Dis J 2003; 22:657-8.
7. U.S. Circular: M-M-RÆII [Measles, Mumps, and Rubella Virus Vaccine Live]. 2002.
8. U.S. Circular: VARIVAX/AX™ [Varicella Virus Vaccine Live (Oka/Merck)]. 2003.
9. Bottiger M, Christenson B, Romanus V, Taranger J, Strandell A. Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella. BMJ 1987; 295:1264-7.
10. Centers for Disease Control and Prevention. Summary of notifiable diseases, United States, 1998. MMWR Morb and Mortal Wkly Rep 1999; 47:1-93.
11. Centers for Disease Control and Prevention. Measles. In: Atkinson W, Wolfe C, Humiston S, Nelson R, eds. Epidemiology and prevention of vaccine-preventable diseases. 6 ed. Atlanta (GA): Centers for Disease Control and Prevention, 2000:115-33.
12. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 2005; 352:450-8.
13. Centers for Disease Control and Prevention. Varicella-related deaths, United States, January 2003 - June 2004. MMWR Morb and Mortal Wkly Rep 2005; 54:272-4.
14. Seward JF, Watson BM, Peterson CL, Mascola L, Pelosi JW, Zhang JX, Maupin TJ, Goldman GS, Tabony LJ, Brodovicz KG, Jumaan AO, Wharton M. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002; 287:606-11.
15. Maupin T, Civen R, Jumaan A, Xiao H, Seward J, Mascola L. Varicella outbreaks in an active surveillance site; Antelope Valley, CA, 1995-2003. Abstract presented at the 38th Annual National Immunization Conference, Nashville, TN. May 11-14, 2004.
16. Clements DA, Zaref JI, Bland CL, Walter EB, Coplan PM. Partial uptake of varicella vaccine and the epidemiological effect on varicella disease in 11 day-care centers in North Carolina. Arch Pediatr Adolesc Med. 2001; 155:455-61.
17. Vázquez M, LaRussa P, Gershon A, Steinberg SP, Freudigman K, Shaprio ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001; 344:955-60.
18. Vázquez M, LaRussa P, Gershon A, Niccolai LM, Muehlenbein CE, Steinberg SP, Shapiro ED. Effectiveness over time of varicella vaccine. JAMA. 2004; 291:851-5.
19. Clements D, Moreira S, Coplan P, Bland C, Walter E. Postlicensure study of varicella vaccine effectiveness in a day-care setting. Pediatr Infect Dis J 1999; 18:1047-50.
20. Centers for Disease Control and Prevention. National, state, and urban vaccination coverage among children aged 19-35 months - United States, 2004. MMWR Morb and Mortal Wkly Rep 2005; 54:717-21.
21. Shinefield HR, Black SB, Digilio L, Reisinget K, Blatter M, Gress JO, Hoffman Brown ML, Eves KA, Olsen Klopfer S, Schödel S, Kuter BJ. Evaluation of a Quadrivalent Measles, Mumps, Rubella, and Varicella Vaccine in Healthy Children. Ped Infect Dis J 2005; 24:665-9.
22. Shinefield HR, Black S, Williams WR, Marchant C, Reisinger K, Stewart T, Meissner HC, Guerrero J, Olsen Klopfer S, Xu J, Schödel F, Kuter BJ and The Dose Selection Study Group for ProQuad®. Dose-Response Study of a Quadrivalent Measles, Mumps, Rubella, and Varicella Vaccine in Healthy Children. Fed Infect Dis J 2005; 24:670-5.
23. Reisinger K, Hoffman Brown ML, Xu J, Sullivan BJ, Marshall GS, Nauert B, Maison DO, Silas PE, Protocol 014 Study Group for ProQuad, Schödel F, Gress JO, Kuter BJ. A combination measles, mumps, rubella, and varicella vaccine (ProQuad™) in 4- to 6-year old healthy children previously vaccinated with M-M-R™II and VARIVAX™. Pediatrics. 2006; 117:265-72.
24. Watson BM, Laufer DS, Kuter BJ, Staehle B, White CJ. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMRIIV) in healthy children. J Infect Dis 1996; 173:731-4.
25. White CJ, Stinson D, Staehle B, Cho I, Matthews H, Ngai A, Keller P. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Clin Infect Dis 1997; 24:925-31.
26. Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hanzel J, Klopfer S, Schödel F, Kuter BJ and the Consistency Lot Study Group for ProQuad. Evaluation of the safety and immunogenicity of a quadrivalent measles, mumps, rubella, and varicella vaccine in healthy children: a study of the manufacturing consistency and persistence of antibody. Ped Infect Dis J 2006; 25:615-22.
27. Shinefield HS, Black SB, Thear M, Corny D, Reisinger K, Rothstein E, Xu J, Hartzel J, Evans B, Digilio L, Schödel F, Hoffman Brown ML, Kuter BJ and the 013 Study Group for ProQuadl. Safety, Tolerability, and Immunogenicity of a Measles, Mumps, Rubella, and Varicella Vaccine Given Concomitantly Versus Nonconcomitantly with Combined Haemophilus b Conjugate/Hepatitis B Vaccines & Combined Diphtheria/Tetanus/Acellular Pertussis Vaccines. Fed Infect Dis J 2006; 25:287-92.
28. Shehab ZM, Brunell PA, Cobb E. Epidemiological standardization of a test for susceptibility to mumps. J Infect Dis 1984; 149:810-2.
29. Johnson CE, Kumar ML, Whitwell JK, Staehle BO, Rome LP, Dinakar C, Hurni W, Nalin DR. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Pediatr Infect Dis J. 1996 Äug; 15:687-92.
30. Keller PM, Lonergan K, Neff BJ, Morton DA, Ellis RW. Purification of individual varicellazoster virus (VZV) glycoprotiens gp1, gp11, and gp111 and their use in ELISA for detection of VZV glycoprotein-specific antibodies. J Virol Methods 1986; 14:177-88.
31. Wasmuth EH, Miller WJ. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol 1990; 32:189-93.
32. Provost PJ, Krah DL, Kuter BJ, Morton DH, Schofield TL, Wasmuth EH, White CJ, Miller WJ, Ellis RW. Antibody assay suitable for assessing immune responses to live varicella vaccine. Vaccine 1991; 9:111-6.
33. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, Orenstein WA. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-42.
34. Hilleman MR, Weibel RE, Buynak EB, Stokes J, Whitman JE. Protective efficacy as measured in a field evaluation. N Engl J Med 1967; 276:252-8.
35. Stokes J, Jr., Weibel RE, Buynak EB, Hilleman MR. Protective efficacy of duck embryo rubella vaccines. Pediatrics 1969; 44:217-24.
36. Li S, Chan I, Matthews H, Heyes JF, Chan CY, Kuter BJ, Kaplan KM, Vessey SJR, Sadoff JC. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J, 2002; 21:337-42.
37. Ratnam S, Gadag V, West R, Burris J, Oates E, Stead F, Bouilianne N. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J Clin Microbiol 1995; 33:811-5.
38. Ward JI, Greenberg DP, Anderson PW, Burkart KS, Christenson PD, Gordon LK, Kayhty H, Kuo JSC, Vella P. Variable quantitation of Haemophilus influenza type b anticapsular antibody by radioantigen binding assay. J Clin Microbiol 1988; 26:72-8.
39. Hollinger FB, Adam E, Heiberg D, Melnick JL. Response to hepatitis B vaccine in a young adult population. In: Szmuness W, Alter HJ, Maynard JE, eds. Viral Hepatitis: 1981 International Symposium. Philadelphia, PA: The Franklin Institute Press, 1982:451-66.
40. Aggerbeck H, Heron I. Improvement of a Vero Cell Assay to Determine Diphtheria Antitoxin Content in Sera. Biologicals 1991; 19:71-6.
41. White CJ, Kuter BJ, Ngai A, Hildebrand CS, Isganitis KL, Patterson CM, Capra A, Miller WJ, Krah DL, Provost PJ, Ellis RW, Calandra GB. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 1992; 11:19-23.
42. Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B, Reisinger K, Kim LL, Lupinacci L, Hartzcl J, Chan I, The Study Group for VARIVAX. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr. Infect. Dis. J., 2004; 23:132-7.
43. Mallet E, Belohradsky BH, Lagos R, Gothefors L, Gamier P, Carrière JP, Güler K, Hoffenbach A, Langue J, Undreiner F, Roussel F, Reinert P, Flodmark CE, Stojanov S, Liese J, Levine MM, Muñoz A, Schödel F, Hessel L, On behalf of the Hexavalent Vaccine Trial Study Group. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogeniciry and safety. Vaccine 2004; 22:1343-57.
44. Weibel RE, Buynak EB, McLean AA, Hilleman MR. Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines. Pediatrics 1978; 61:5-11.
45. Hirtz DG. Febrile seizures. Pediatr Rev 1997; 18:5-8.
46. Freeman JM, Vining EPG. Decision making and the child with febrile seizures. Pediatr Rev 1992; 13:298-304.
47. Barlow WE, Davis RL, Classer JW, Rhodes PH, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Ward JI, Marcy SM, DeStefano F, Chen RT, the Centers for Disease Control and Prevention Vaccine Safety Datalink Working Group. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001; 345:656-61.
48. Pebody RG, Gay NJ, Hesketh LM, Hesketh LM, Vyse A, Morgan-Capner P, Brown DW, Litton P, Miller E. Immunogencity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance. Vaccine 2002; 20:1134-40.
49. Centers for Disease Control and Prevention. Measles, mumps and rubella - vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps. MMWR Morb and Mortal Wkly Rep 1998; 47:1-57.
50. Centers for Disease Control and Prevention Media Relations. Press Release: CDC's advisory committee recommends changes in varicella recommendations, http://www.cdc.gov/od/oc/media/pressrel/r060629-b.htm.
51. Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 1994; 140:81-104.
52. McIntosh K. Varicella vaccine: Decisions a little nearer. N Engl J Med 1984; 310:1456-7.
53. Schuette MC, Hethcote H. Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles. Bull Math Biology 1999; 61:1031-64.
54. World Health Organization. Immunization in practice. A practical resource guide for health workers-2004 update. 2004:2-26.
55. National Advisory Committee on Immunization. Canadian immunization guide 2002:143-50.